Steatotic liver disease spectrum: From MASLD to MetALD and beyond - Clinical outcomes and precision medicine frontiers Authors: Won Kim Published: 2026 The 2023 multisociety Delphi consensus did far more than rename a disease. By replacing non-alcoholic fatty liver disease with metabolic dysfunction-associated steatotic liver disease (MASLD), and by introducing metabolic and alcohol-associated liver disease (MetALD) and alcohol-associated liver disease (ALD) under the umbrella of steatotic liver disease (SLD), the new nomenclature formally acknowledged a clinical reality that hepatologists have long recognized at the bedside: metabolic dysfunction and alcohol exposure frequently coexist in the same patient, interact synergistically, and shape prognosis along a continuous, and modifiable, spectrum rather than within mutually exclusive diagnostic silos. Three years on, the SLD framework has moved from nomenclature debate to the harder questions of implementation: how large is the burden of each subtype, and how reliably can we distinguish them? Which mechanisms and genetic modifiers drive divergent trajectories? How should alcohol exposure be quantified and integrated into risk stratification? And how do we translate an expanding therapeutic armamentarium into individualized care? To address these questions, Clinical and Molecular Hepatology commissioned this special review series, “Steatotic liver disease spectrum: From MASLD to MetALD and beyond - Clinical outcomes and precision medicine frontiers.” The ten state-of-the-art reviews assembled in this issue, contributed by leading investigators from Asia, North America, Europe, and Latin America, traverse the full arc of the field, from global epidemiology and molecular pathophysiology, through genetics, non-invasive assessment, risk prediction, and alcohol-aware care pathways, to clinical outcomes, dual-etiology disease, and the rapidly evolving therapeutic landscape. In this editorial, I briefly introduce each contribution and the narrative thread that connects them. The series opens with the epidemiological foundation. Danpanichkul et al. [1] synthesize contemporary data on the global patterns and disease burden of MASLD, MetALD, and ALD, showing that MASLD now affects approximately 30–40% of adults worldwide, with the steepest rises in regions with lower sociodemographic indices, while MetALD (an estimated 2–8% of adults, likely underestimated owing to underreported alcohol intake) and ALD contribute disproportionately to severe liver-related morbidity and mortality. Their review underscores that mitigating the SLD epidemic will require public health policies that jointly target metabolic risk prevention, alcohol regulation, and early risk stratification. Two reviews then dissect the biological substrate of the spectrum. Lee et al. [2] present a “precision pathophysiology” perspective on SLD, delineating the shared and distinct molecular features of MASLD and MetALD and highlighting how multi-omic technologies, integrated single-cell genetic, epigenetic, spatial, and proteomic profiling, together with human liver spheroids and refined animal models can capture the synergistic effects of alcohol and metabolic stress and accelerate target discovery. Complementing this mechanistic view, Mann et al. [3] review genetic and genomic insights across the SLD spectrum, from the well-replicated variants in PNPLA3, TM6SF2, and HSD17B13 that modulate cirrhosis and hepatocellular carcinoma risk in both MASLD and ALD, to steatosis-predominant loci such as GCKR, TRIB1, and GPAM. They argue persuasively that the largely shared genetic architecture of MASLD and ALD predicts similar genetic risk factors in MetALD, and they chart a course toward genetically defined disease subtypes, gene-environment interaction studies, and genetics-informed clinical risk stratification. Four reviews form the diagnostic and prognostic core of the series. Tincopa and Loomba [4] provide a comprehensive appraisal of non-invasive assessment and biomarkers across MASLD, MetALD, and ALD, emphasizing that the performance of non-invasive tests (NITs) varies substantially by test, cut-point, and population, with the strongest evidence base in MASLD, comparatively limited data in ALD, and only emerging data in MetALD. Lin et al. [5] then focus on risk assessment in MASLD and MetALD, outlining the contemporary sequential strategy, simple serum scores such as Fibrosis-4 (FIB-4) followed by elastography or liver-specific blood tests, and looking ahead to dynamic longitudinal NIT measurement, integration of cardiovascular and kidney risk, objective alcohol biomarkers such as phosphatidylethanol (PEth), and artificial intelligence-driven personalized risk and treatment prediction. Girard et al. [6] extend this discussion from individual tests to systems of care, reviewing predictive modeling and clinical decision tools for risk stratification in SLD. They propose a consensus risk stratification care pathway adaptable to diverse clinical settings and distill the factors critical to successful clinical decision support, workflow integration, minimal clinician burden, point-of-care delivery, and continuous local evaluation. Finally, Lee et al. [7] tackle what is arguably the Achilles’ heel of the entire SLD framework: the assessment of alcohol exposure. Their review of alcohol-aware risk stratification and subtype-specific care pathways demonstrates how reliance on self-report drives subtype misclassification, how structured questionnaires and objective biomarkers such as PEth can be triangulated, and how active alcohol use modifies the interpretation of FIB-4 and liver stiffness measurement, culminating in practical, subtype-specific care pathways spanning MASLD, MetALD, and ALD. What ultimately matters to patients is prognosis. Lee et al. [8] synthesize cardiovascular and hepatic outcomes across the MASLD-MetALD-ALD continuum, describing a prognostic reorientation in which cardiovascular disease accounts for 40–50% of deaths in MASLD, whereas liver-related mortality predominates in ALD, with hepatic outcomes rising stepwise with alcohol exposure and advanced fibrosis acting as the shared amplifier of both cardiovascular and hepatic risk. Their proposal to embed non-invasive fibrosis assessment, alcohol biomarkers, and cardiovascular risk calculators within the cardiovascular-kidney-metabolic framework exemplifies the outcome-oriented, multisystem approach this series advocates. Beyond the metabolic-alcohol axis, the SLD spectrum increasingly intersects with viral hepatitis. Huang et al. [9] examine chronic viral hepatitis with concurrent MASLD, illuminating the intriguing “steatosis paradox” in chronic hepatitis B, whereby hepatic steatosis may favor viral clearance even as the systemic cardiometabolic burden dose-dependently drives fibrogenesis and hepatocellular carcinoma, and the synergistic injury of hepatitis C and metabolic dysfunction that persists even after viral eradication. Their call to move from a virocentric paradigm toward a dual-target strategy of viral suppression plus aggressive metabolic remission is timely and clinically actionable. The series closes where patients’ hopes are highest. Bong et al. [10] chart the evolution of the therapeutic landscape for SLD, from lifestyle modification anchored in the Mediterranean diet to the first regulatory approvals of resmetirom and semaglutide for non-cirrhotic metabolic dysfunction-associated steatohepatitis with moderate-to-advanced fibrosis, and onward to the rich pipeline of incretin-based therapies, fibroblast growth factor-21 analogues, and mechanism-targeted agents. Importantly, they confront the therapeutic vacuum in MetALD, where management still rests on alcohol cessation and cardiometabolic optimization, and articulate a precision medicine paradigm that tailors pharmacologic and lifestyle interventions to disease phenotype, genetic risk, and the gut microbiome. Several themes recur throughout this series and merit emphasis. First, fibrosis stage remains the dominant determinant of liver-related outcomes across all SLD subtypes, but prognostication can no longer be liver-centric: cardiovascular and kidney risks must be assessed and managed in parallel. Second, accurate and objective quantification of alcohol exposure, increasingly feasible with biomarkers such as PEth, is a prerequisite for valid subtype classification, reliable NIT interpretation, and meaningful clinical trials in MetALD, which remains the least understood and most understudied subtype. Third, the convergence of genetics, multi-omics, artificial intelligence, and implementation science is transforming SLD care from population-level algorithms toward genuinely individualized risk prediction and treatment selection. The precision medicine frontier is no longer aspirational; it is the organizing principle of the field’s next decade. On behalf of the editorial board of Clinical and Molecular Hepatology, I express my deepest gratitude to the authors, who generously contributed their expertise and time, and to the reviewers whose rigorous critiques strengthened every manuscript in this series. It is my hope that this collection will serve as both a definitive reference for clinicians and investigators navigating the SLD spectrum and a catalyst for the collaborative, mechanism-informed, and patient-centered research that the field now demands. Abbreviations alcohol-associated liver disease Fibrosis-4 metabolic dysfunction-associated steatotic liver disease metabolic and alcohol-associated liver disease non-invasive test phosphatidylethanol steatotic liver disease Footnotes Authors’ contribution WK designed and wrote the manuscript. Conflicts of Interest The author has no conflicts of interest to disclose in relation to this editorial. REFERENCES